We are a CRO based at the heart of the Barcelona Science Park. We specialise in Medicinal Chemistry, Chemical R&D and Solid State R&D.

Contact us to find out how our expertise in Cocrystals and Asymmetric Synthesis can help your project succeed.

A bond you can count on

We are a CRO based at the heart of the Barcelona Science Park. We specialise in Medicinal Chemistry, Chemical R&D and Solid State R&D.

Contact us to find out how our expertise in Cocrystals and Asymmetric Synthesis can help your project succeed.

Our Services

Medical Chemistry Enantia Barcelona

Medicinal
Chemistry

Our platform has a solid background in the design and synthesis of small molecules as ligands for a broad range of therapeutic targets.
We can contribute in the different stages of a drug discovery program.

Learn more

Chemical and process Enantia

Chemical
R&D

Chemistry that works. We work continuously in the resolution of chemical challenges, the design of new routes of synthesis, and the creation of valuable processes for fine chemical, pharmaceutical and biotechnology industry.

Learn more

Solid State R&D

Solid State
R&D

Crystallising your ideas. We can help you through the entire process of solid form selection, from initial screening, analysis, characterisation and performance tests to development and scale-up and long-time stability tests.

Learn more

Our History

  • 2018

    Enantia’s 15th anniversary

    In 2018 Enantia celebrates its 15th anniversary.
    Furthermore, during 2018 Enantia opens its new offices in the Barcelona Science Park, which consolidate the growth of the company over the years.
  • 2016

    Patent Milestone: 50

    During 2016 Enantia filed its 50th patent.

  • 2015

    Licensing of Esteve and Mundipharma

    An innovative cocrystal, obtained by Enantia working in collaboration with Esteve R&D, is part of the global partnership announced by Esteve and Mundipharma-Purdue.

  • 2014

    Collaboration with the ALBA Synchrotron light

    Start of the ALBA synchrotron collaboration, the most important light facility in the south of Europe.

    Since 2014, here at Enantia we have taken advantage of the ALBA’s light beam, allowing us to reach even higher resolution and greater sensitivity. With the in house diffractometer we are already able to characterise a crystaline structure, however with the ALBA beamline we are able to tackle the most challenging projects.

    The same year we celebrated filing our 40 th patent.

  • 2013

    European consortium Nano3Bio

    Enantia enters in the Nano3Bio’s international scientific project in the field of biotechnology. Its goal is the breakthrough from basic research to biotechnological production of chitosans. The consortium represents eight countries (six universities, two research centres, 13 start-up or well established SMEs and one large company).

  • 2012

    New commercial office in Italy

    Enantia opens its first commercial office in Milan (Italy) and starts its Medicinal ChemistryDepartment.

  • 2011

    Senén Vilaró Prize

    The company is awarded the 2011 Senén Vilaró Prize. The Bosch i Gimpera Foundation (University of Barcelona) gives this prize as a recognition of Enantia’s track record in transferring its scientific and technical knowledge back to society.

  • 2010

    Enantia, selected by Neogenius as preferred partner

    Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the Neogenius project kicks off and runs for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.

    Enantia is selected as custom synthesis provider to support the drug discovery activities of the consortium.

  • 2009

    Patent Milestone: 20

    Enantia files its 20th patent.

  • 2008

    Pimec Prize for the most competitive company

    Enantia is awarded the 2008 Pimec Prize (Premis Pimec) for the most competitive small company. This prize was given personally by the King of Spain Juan Carlos I to the then CEO Llorenç Rafecas during a dinner in Barcelona. Pimec is the association that represents the micro, small and medium-sized companies in Catalonia.

  • 2007

    New Crystal Engineering Department

    Enantia opens its third laboratory in Esplugues de Llobregat to start its Crystal Engineering Department. The area is where 90% of the Catalan life science sector calls home.

  • 2006

    CENIT R&D project

    Genius Pharma, a consortium led by the three major Spanish pharmaceutical companies in which Enantia plays one of the leading roles, wins a CENIT R&D project (CDTI). The main objective of the project is to develop, build and exploit technology platforms and best practices in the drug discovery process.

  • 2004

    Inauguration of the second lab

    Enantia opens a second laboratory dedicated to synthesis.

  • 2003

    Success in tech transfer

    Enantia is created as a spin-off of the University of Barcelona with headquarters in the Barcelona Science Park. The initial team is composed of eight people including Mr. Llorenç Rafecas as CEO, a professional with 24 years of experience in the fine chemicals industry, with executive responsibilities in chemical R&D.